Anja Seckinger, Vanessa Buatois, Valéry Moine, Bruno Daubeuf, Françoise Richard, Laurence Chatel, Alizée Viandier, Nicolas Bosson, Emeline Rousset, Krzysztof Masternak, Susana Salgado-Pires, Claudia Batista, Christelle Mougin, Flora Juan-Bégeot, Yves Poitevin, Dirk Hose
BACKGROUND: Blocking the CD47 "don't eat me"-signal on tumor cells with monoclonal antibodies or fusion proteins has shown limited clinical activity in hematologic malignancies and solid tumors thus far. Main side effects are associated with non-tumor targeted binding to CD47 particularly on blood cells. METHODS: We present here the generation and preclinical development of NILK-2401, a CEACAM5×CD47 bispecific antibody (BsAb) composed of a common heavy chain and two different light chains, one kappa and one lambda, determining specificity (so-called κλ body format)...
2024: Frontiers in Immunology